Side Effects: The Nose Knows - Summary - MDSpire

Side Effects: The Nose Knows

A nasal swab may detect Alzheimer's before symptoms appear — and the immune system is already loud about it

  • By

  • Kerri Miller

  • March 18, 2026

  • 6 min

Share

Objective:

To explore the detection of pre-clinical Alzheimer's disease through olfactory epithelium biopsies.

Approach:
    Key Findings:
    • Pre-clinical Alzheimer's group showed activated CD8 memory T cells in olfactory tissue at rates nearly triple that of controls (13.4% vs. 4.1%, p=0.017).
    • The olfactory T-cell activation pattern in pre-clinical Alzheimer's mirrors findings in the CSF of patients with clinical Alzheimer's.
    • A combined immune plus neuronal gene module classified preclinical versus control with an AUC of 0.81.
    Interpretation:

    Olfactory loss in older patients may indicate early biological changes associated with Alzheimer's disease, suggesting the nose could serve as a diagnostic tool.

    Limitations:
    • The biopsy approach is not yet clinical.
    • The study sample size was small (n=22).
    Conclusion:

    The findings highlight the potential of olfactory biopsies as a diagnostic method for early Alzheimer's detection, reframing the importance of olfactory health.

    Sources:

Original Source(s)

Side Effects: The Nose Knows

  • by Kerri Miller

  • March 18, 2026

Related Content

Case Report: Erythema gyratum repens associated with adenomyosis and endometriosis: an immunological twist?

Low Vitamin D Persists Year-Round in Northern Britain

Screening data from a UK clinical trial found low vitamin D levels in 55% of older patients and 72% of ethnic patients, with little variation despite summer months.

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.